Selskab med fokus på psoriasis og gigt går på børsen
Selskabet CS Medica, der står bag en række cannabis-holdige produkter til behandling af psoriasis og gigt i håndkøb børsnoteres senere i år på vækstbørsen Spotlight for at rejse kapital til blandt andet yderligere ekspansion på de europæiske markeder.
Et dansk selskab med fokus på cannabis-holdige produkter til behandling af psoriasis og gigt er klar til at ringe med børsklokken, hvor selskabet i årets tredje kvartal vil rejse kapital til især at kunne kapre større bidder af det europæiske marked.
For more information about CS MEDICA:
Lone Henriksen, CEO
Phone: + (45) 70 70 73 37
Direct: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/
CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.
The company is listed on Spotlight Stockmarked Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.
Advisors, selling agent, and issuing agency
Sedermera Fondkommission is the financial advisor, Phone: +46 (0) 40 615 14 10, info@sedermera.se. Markets & Corporate Law Nordic is the legal advisor to CS MEDICA in connection with the planned capitalization and listing. Nordic Issuing acts as issuing agency and Nordnet Bank AB is the selling agent.
